Last quarter (Q3 2023), Better Therapeutics, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Better Therapeutics, Inc.'s net income was $-5.86M. See Better Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	$ 8.00K	$ 18.00K
Cost of Revenue	-	-	-	$ 682.00K	$ 898.00K
Gross Profit	-	-	-	$ -674.00K	$ -880.00K
Operating Expense	$ 12.97M	$ 38.26M	$ -30.56M	$ 6.33M	$ 4.89M
Operating Income	$ -29.61M	$ -38.26M	$ -30.56M	$ -6.32M	$ -5.77M
Net Non Operating Interest Income Expense	$ -1.95M	$ -1.49M	$ -185.00K	$ -100.00K	$ -11.00K
Other Income Expense	-	-	$ -647.00K	$ 189.00K	-
Pretax Income	$ -31.56M	$ -39.75M	$ -40.49M	$ -6.23M	$ -5.78M
Tax Provision	$ 9.00K	$ 7.00K	$ -153.00K	$ 153.00K	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -31.57M	$ -39.76M	$ -40.34M	$ -7.89M	$ -7.16M
Basic EPS	$ -1.57	$ -1.69	$ -3.11	$ -0.33	$ -0.30
Diluted EPS	$ -1.16	$ -1.69	$ -3.11	$ -0.33	$ -0.30
Basic Average Shares	$ 117.09M	$ 23.56M	$ 12.98M	$ 23.60M	$ 23.60M
Diluted Average Shares	$ 117.09M	$ 23.56M	$ 12.98M	$ 23.60M	$ 23.60M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 12.97M	$ 38.26M	$ -30.56M	$ 6.33M	$ 5.79M
Net Income From Continuing And Discontinued Operation	$ -31.57M	$ -39.76M	$ -40.34M	$ -6.39M	$ -5.78M
Normalized Income	$ -10.62M	$ -31.40M	-	$ -6.52M	$ -5.78M
Interest Expense	-	-	-	$ 100.00K	$ 11.00K
EBIT	$ -29.61M	$ -38.26M	$ -40.30M	$ -6.13M	$ -5.77M
EBITDA	$ -22.00M	$ -35.53M	$ -38.68M	$ -6.06M	$ -5.70M

Currency in USD

Better Therapeutics, Inc. Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing